[Translation] A single-center, randomized, open-label, two-formulation, single-dose, two-period, two-sequence crossover postprandial bioequivalence study of merogabarine besylate tablets (5 mg) in healthy subjects.
主要目的:以石家庄龙泽制药股份有限公司提供的苯磺酸美洛加巴林片(规格:5mg)为受试制剂,按生物等效性试验的有关规定,与第一三共株式会社生产的苯磺酸美洛加巴林片(商品名:Tarlige®,规格:5mg)作为参比制剂,对比在健康人体内的吸收速度及吸收程度,考察两制剂的人体生物等效性。
次要目的:观察受试制剂苯磺酸美洛加巴林片(T,规格:5mg)和参比制剂苯磺酸美洛加巴林片(R,商品名:Tarlige®,规格:5mg)在健康受试者中的安全性
[Translation] Primary Objective: To compare the absorption rate and extent of merogalaline besylate tablets (5 mg) provided by Shijiazhuang Longze Pharmaceutical Co., Ltd. with merogalaline besylate tablets (T, 5 mg) manufactured by Daiichi Sankyo Co., Ltd. (Taiwanese brand name: Tarlige®, 5 mg) as the reference formulation in healthy subjects, in accordance with relevant regulations for bioequivalence studies, and to examine the human bioequivalence of the two formulations.
Secondary Objective: To observe the safety of the test formulation merogalaline besylate tablets (T, 5 mg) and the reference formulation merogalaline besylate tablets (R, Tarlige®, 5 mg) in healthy subjects.